HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CEBPG
CCAAT enhancer binding protein gamma
Chromosome 19 · 19q13.11
NCBI Gene: 1054Ensembl: ENSG00000153879.10HGNC: HGNC:1837UniProt: P53567
53PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Transcription Factor
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
positive regulation of DNA repairpositive regulation of transcription by RNA polymerase IInucleoplasmprotein bindingneurodegenerative diseasetype 2 diabetes mellituspsoriasisovarian neoplasm
✦AI Summary

CEBPG (CCAAT enhancer binding protein gamma) is a sequence-specific DNA-binding transcription factor that regulates gene expression across multiple biological processes. CEBPG functions as both a transcriptional activator and corepressor, binding to CCAAT elements and other regulatory sequences in target gene promoters and enhancers 1. It forms heterodimeric complexes with other transcription factors like ATF4 to regulate target genes 2. In disease contexts, CEBPG plays significant roles in cancer progression and metabolic stress responses. CEBPG suppresses ferroptosis in ovarian cancer by transcriptionally activating SLC7A11, a key ferroptosis inhibitor, and elevated CEBPG expression correlates with poor prognosis 3. In nasopharyngeal carcinoma, CEBPG mRNA stability is enhanced through ac4C acetylation, promoting immunosuppression and T-cell dysfunction 4. CEBPG also regulates DNA repair gene ERCC5 expression in bronchial epithelial cells, with polymorphisms potentially contributing to lung cancer risk 1. Additionally, CEBPG acts as a key transcriptional regulator in dedifferentiated cardiomyocytes during atrial fibrillation remodeling 5, and serves as a critical transcription factor in mesenchymal glioblastoma 6. CEBPG participates in protective responses against lipotoxicity by co-regulating RETREG1-mediated reticulophagy 2 and regulates CCR2 transcription in bladder cancer development 7.

Sources cited
1
CEBPG is overexpressed in ovarian cancer, associates with poor prognosis, and suppresses ferroptosis through transcriptional control of SLC7A11
PMID: 37210575
2
NAT10-mediated ac4C modification of CEBPG mRNA improves its stability and translation efficiency, contributing to nasopharyngeal carcinoma immunosuppression
PMID: 39939141
3
CEBPG forms a heterodimer with ATF4 to transcriptionally upregulate RETREG1, mediating reticulophagy and protection against lipotoxicity
PMID: 40437698
4
CEBPG regulates ERCC5/XPG DNA repair gene expression through binding to recognition sites in the promoter region, with regulation modified by E2F1/YY1 interactions
PMID: 17893230
5
CEBPG is a key transcription factor regulating gene expression patterns in dedifferentiated cardiomyocytes during atrial fibrillation
PMID: 37722560
6
CEBPG is identified as an upregulated ferroptosis regulator in colorectal cancer with increased H3K27ac enhancer signals
PMID: 38032469
7
CEBPG is a transcription factor for CCR2 and binds with NUPR1 to regulate CCR2 transcription in bladder cancer
PMID: 39149887
8
CEBPG is identified as a key transcription factor specific to the mesenchymal subtype of glioblastoma through integrated single-cell multi-omics analysis
PMID: 39707474
Disease Associationsⓘ20
neurodegenerative diseaseOpen Targets
0.47Moderate
type 2 diabetes mellitusOpen Targets
0.33Weak
psoriasisOpen Targets
0.26Weak
ovarian neoplasmOpen Targets
0.25Weak
acute myeloid leukemiaOpen Targets
0.08Suggestive
glioblastoma multiformeOpen Targets
0.07Suggestive
breast cancerOpen Targets
0.07Suggestive
Abnormality of the skeletal systemOpen Targets
0.05Suggestive
diabetes mellitusOpen Targets
0.04Suggestive
pulmonary alveolar proteinosis with hypogammaglobulinemiaOpen Targets
0.04Suggestive
primary ciliary dyskinesiaOpen Targets
0.03Suggestive
autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicityOpen Targets
0.03Suggestive
neoplasmOpen Targets
0.03Suggestive
alcohol drinkingOpen Targets
0.03Suggestive
Abruptio PlacentaeOpen Targets
0.03Suggestive
Wiskott-Aldrich syndromeOpen Targets
0.03Suggestive
antipsychotic drug related weight gainOpen Targets
0.03Suggestive
colorectal cancerOpen Targets
0.03Suggestive
gestational diabetesOpen Targets
0.03Suggestive
metabolic syndromeOpen Targets
0.03Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
JUNProtein interaction100%FOSProtein interaction99%CIITAProtein interaction92%TRIB3Protein interaction89%JDP2Protein interaction81%DDIT3Protein interaction78%
Tissue Expression6 tissues
Brain
100%
Liver
32%
Bone Marrow
25%
Lung
19%
Heart
17%
Ovary
5%
Gene Interaction Network
Click a node to explore
CEBPGJUNFOSCIITATRIB3JDP2DDIT3
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt P53567
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
1.07LoF Tolerant
pLIⓘ
0.04Tolerant
Observed/Expected LoF0.57 [0.32–1.07]
RankingsWhere CEBPG stands among ~20K protein-coding genes
  • #8,405of 20,598
    Most Researched53
  • #10,842of 17,882
    Most Constrained (LOEUF)1.07
Genes detectedCEBPG
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
CEBPG suppresses ferroptosis through transcriptional control of SLC7A11 in ovarian cancer.
PMID: 37210575
J Transl Med · 2023
1.00
2
Acetyltransferase NAT10 inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5/HMGB1 axis.
PMID: 39939141
J Immunother Cancer · 2025
0.90
3
RETREG1-mediated reticulophagy is activated by an ATF4-CEBPG/C/EBPγ heterodimer and confers protection against lipotoxicity.
PMID: 40437698
Autophagy · 2025
0.80
4
CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions.
PMID: 17893230
Carcinogenesis · 2007
0.70
5
Deciphering mechanisms of cardiomyocytes and non-cardiomyocyte transformation in myocardial remodeling of permanent atrial fibrillation.
PMID: 37722560
J Adv Res · 2024
0.60